These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22154113)

  • 21. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
    Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N
    Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
    Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
    Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
    Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
    Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
    Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
    Burotto M; Ali SA; O'Sullivan Coyne G
    Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
    Krozely P
    Clin J Oncol Nurs; 2004 Apr; 8(2):163-8. PubMed ID: 15108418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
    Costa DB
    Lung Cancer; 2007 Aug; 57(2):251-2. PubMed ID: 17566601
    [No Abstract]   [Full Text] [Related]  

  • 29. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
    Shao YY; Lin CC; Yang CH
    Discov Med; 2010 Jun; 9(49):538-45. PubMed ID: 20587343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR inhibitors in lung cancer.
    Buter J; Giaccone G
    Oncology (Williston Park); 2005 Nov; 19(13):1707-11; discussion 1711-2, 1720-3. PubMed ID: 16425523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
    Laack E; Sauter G; Bokemeyer C
    Lung Cancer; 2010 Sep; 69(3):259-64. PubMed ID: 20646778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BIBW 2992 in non-small cell lung cancer.
    Subramaniam DS; Hwang J
    Expert Opin Investig Drugs; 2011 Mar; 20(3):415-22. PubMed ID: 21320004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
    Giaccone G
    J Clin Oncol; 2005 May; 23(14):3235-42. PubMed ID: 15886311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.
    Ho C; Davies A; Mack P; Gandara D
    Clin Lung Cancer; 2007 Jul; 8(7):420-4. PubMed ID: 17681094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
    DeGrendele H
    Clin Lung Cancer; 2003 Sep; 5(2):83-5. PubMed ID: 14596689
    [No Abstract]   [Full Text] [Related]  

  • 36. Recent developments related to the EGFR as a target for cancer chemotherapy.
    Speake G; Holloway B; Costello G
    Curr Opin Pharmacol; 2005 Aug; 5(4):343-9. PubMed ID: 15950538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
    Bunn PA
    J Clin Oncol; 2007 Jun; 25(18):2504-5. PubMed ID: 17577025
    [No Abstract]   [Full Text] [Related]  

  • 38. Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients.
    Nishio M; Ohyanagi F; Horiike A; Ishikawa Y; Satoh Y; Okumura S; Nakagawa K; Nishio K; Horai T
    Br J Cancer; 2005 May; 92(10):1877-80. PubMed ID: 15870715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lung cancer: looking ahead in 2004.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2004 Jan; 5(4):200. PubMed ID: 14967070
    [No Abstract]   [Full Text] [Related]  

  • 40. Overview of tyrosine kinase inhibitors in clinical breast cancer.
    Agrawal A; Gutteridge E; Gee JM; Nicholson RI; Robertson JF
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S135-44. PubMed ID: 16113090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.